About the event
BioValley matches its members with interesting life science start-ups seeking risk capital and other resources. The focus is on projects located in the Basel area and the trinational BioValley cluster in the area of biotech, pharma, diagnostics and medtech in seed or early stage.
Angel investments may benefit entrepreneurs through exposure to a wider set of potential investors, and a structured process that facilitates relatively quick and efficient investment decisions. Angel investing represents a large and growing portion of early stage capital available to startup companies. Business angels typically invest between CHF 50k and CHF 200k per transaction individually, and from CHF 250k to CHF 1’000k as a group. On average, angels are patient, participate in multiple capital rounds, and have an overall investment horizon of up to eight years. BioValley Basel holds 2-3 events per year with presenting companies selected by screening process. We evaluate based on management team, market opportunity, growth potential, stage, as well as other factors.
Agenda
17:00 - 17:05 Welcome and Introduction
Welcome by Thomas Möller and Sara Nunez-Garcia
17:05 - 17:50 Company Pitches (10min + 5minQ&A)
Pharmabiome – Dr. Tomas Wouters (CEO) - Schlieren/Allschwil
Innovative company in the microbiome space. PharmaBiome has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale.
TheraPPI – Luc Otten (CEO) – Lyon/CH
Company develops a new class of protein interaction inhibitors to tackle drug resistance in cancer and to cure other rare diseases.
MachineMD - Dominic Senn (CEO) – Bern
Company developing medical device to radically improve early detection of brain disorders, with the goal to bring diagnostic quality of a highly trained specialist to every doctor, optometrist and optician anywhere.
17:50 Networking & Apéro
Please register for the event at https://biovalleyangels23.events.vischer.com/
00
Days00
Hours00
Minutes